Palatin Technologies (PTN) Operating Income (2010 - 2026)
Palatin Technologies' (PTN) quarterly Operating Income came in at -$1.6 million in Q1 2026, up 67.15% on a YoY basis from -$945837.6 in Q1 2025, and up 78.43% quarter-over-quarter from -$7.3 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Operating Income (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Operating Income for 16 consecutive years, with -$1.6 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 67.15% year-over-year to -$1.6 million; the trailing twelve-month figure through Mar 2026 stood at -$6.5 million (up 72.3% YoY), and the FY2025 full-year result was -$17.5 million, up 22.39% from the prior year.
- Operating Income grew to -$1.6 million in Q1 2026 per PTN's latest filing, from -$7.3 million in the prior quarter.
- Across five years, Operating Income topped out at $4.7 million in Q3 2025 and bottomed at -$13.1 million in Q2 2022.
- Historically, Operating Income has averaged -$5.7 million across 5 years, with a median of -$7.3 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Operating Income plunged 322.59% in 2024, then jumped 160.03% in 2025.
- Over 5 years, Operating Income stood at -$5.6 million in 2022, then soared by 121.0% to $1.2 million in 2023, then slumped by 322.59% to -$2.6 million in 2024, then slumped by 180.65% to -$7.3 million in 2025, then soared by 78.43% to -$1.6 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$1.6 million, -$7.3 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | -1.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1.58 Mn |
| Dec 31, 2025 | -7.33 Mn |
| Sep 30, 2025 | 4.66 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | -4.81 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Sep 30, 2024 | -7.76 Mn |
| Jun 30, 2024 | -8.34 Mn |
| Mar 31, 2024 | -9.22 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Sep 30, 2023 | -6.11 Mn |
| Jun 30, 2023 | -10.82 Mn |
| Mar 31, 2023 | -7.30 Mn |
| Dec 31, 2022 | -5.59 Mn |
| Sep 30, 2022 | -8.75 Mn |
| Jun 30, 2022 | -13.10 Mn |
| Mar 31, 2022 | -7.82 Mn |
| Dec 31, 2021 | -8.45 Mn |
| Sep 30, 2021 | -7.22 Mn |
| Jun 30, 2021 | -13.70 Mn |